Teva’s Austedo guidance for 2025, at $1.9 billion to $2 billion, currently stands lower than Neurocrine's Ingrezza range. While “both brands are doing quite well,” according to Neurocrine ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Monday. A ...

Of the trio, the most drastic cutter was UBS's Ashwani Verma, who reduced his level on Neurocrine to $154 per share from his preceding $176. According to reports, Verma cited uninspiring guidance ...

Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company reported Ingrezza Q4 about 1% below consensus estimates ...

Neurocrine Biosciences Q4 EPS of $1.69 beat estimates, while revenue missed consensus. Ingrezza sales rose 23% to $615 million. 2025 Ingrezza sales guidance fell short of Street estimate. Analysts ...

It's been a soft week for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares, which are down 19%. But we wouldn't complain about the gain over the last three years. In that time the stock gained 43 ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates. Overall, the quarter showcased strong ...

On Thursday, Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company ...

Neurological therapeutics specialist Neurocrine Biosciences (NASDAQ:NBIX) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted ...